# Zealand plans to invest $800 ⁠million in research over the next five years.

*biotech · news · 2026-05-07 · Reuters*

## Key points

- Petrelintide targets a different hormone pathway than Wegovy or Zepbound, aiming for fewer side effects.
- Zealand plans to invest about $800 million in research over the next five years.
- Zealand's cash position was DKK 14.5 billion at the end of March 2024.
- Zealand's 2026 operating expense guidance remains unchanged despite buyback and new spending plans.

**Companies:** Zealand, Roche, Boehringer Ingelheim
**Countries:** Denmark, Switzerland, Germany

[Read the full story on Reuters](https://www.reuters.com/legal/litigation/zealand-pharma-posts-smaller-than-expected-q1-loss-obesity-drugs-advance-2026-05-07/)

---

Canonical: https://newsio.io/n/1f0401a1-1c06-4d4e-91b3-fd71bb61ae55/zealand-plans-to-invest-800-million-in-research-over-the-next-five-years-the-com
Summarized by Newsio from Reuters. https://newsio.io/how-it-works